N
Google TrendLAMINE YAMAL (5000+) — "You want to play for Morocco?": Getafe defender provokes Yamal with shocking words
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:lamine yamal5000+thélyson orélien500+adeyemi500+abdulrahman alfozan500+pope francis500+delaware vs middle tennessee prediction500+bayern de múnich200+pablo torre200+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "LEQEMBI® Subcutaneous Aut" (17 stories)

Top Headline Story

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
Lead StoryBiogengeneral
Jul 13

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNcUkxT1BlZDFLOUFrTkN4UXRqQjBpbXVJclZiU3BabzNCQW5zVnVxUjlGWkc4STlpNXpFYUJZU3VsYndNU2NUZHNMVWltZG5mYXNnVHJKMW4wODUtRUZVZjJIbnRHdHc2dVVBcldHWElRTVdsMWJUUUtLczBreUFpV3FYc0JoTWQ5XzI0SEZQQkw0Z0xUcm5scFRzb0Y5SFpjb1ZoVmNOOTY4SEpkRzJhVWo2cVpFSXJLSlBZ?oc=5" target="_blank">FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
5000+31m ago

lamine yamal

"You want to play for Morocco?": Getafe defender provokes Yamal with shocking words

Filter stories
500+31m ago

thélyson orélien

Acclaimed Author Denies Using A.I. but Admits Plagiarism

Filter stories
500+31m ago

adeyemi

Licensable picture: Galatasaray v Barcelona - UEFA Champions League

Filter stories
500+41m ago

abdulrahman alfozan

Saudi national OpenAI employee arrested after 'sophisticated recording device' planted in office

Filter stories

Search Results for "LEQEMBI® Subcutaneous Aut"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

16 stories displayed
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
PR Newswiretech

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

<a href="https://news.google.com/rss/articles/CBMi-AJBVV95cUxPUy1RMDJWamtRMUFRTDhoNDZONHBLQks1b19XVEkxZ3g1UkZUMEd1dzdrcWRGOV9sR3Zod0RGazRHVFo1cjZHUmJkZ3NzdVAwMmhFRUpEYWN3Ykp1NmxpSHVISmRqN1JVY2MyX01TN0FmcXhvM24yYU1TMDc0NUFSbDFiQjhFSUJxRTBRS3hadXJQbUlLX2MwZng0VTVZQy1XMVZ5VnN2N1FZdC12NDN3SVkybThVbVlpcDR2N0JCTlJhb3h6Y2pwVE55akhwTXJyN0t0QU5CSzk5aVdDQW9yNzI2eEVtMUUxS1V5ZW1iOWlxYWU1LWgybTNhZkpRSzQyX2tTcy1EV0RyNWs3TWx5SUUzbHdwQ0hlZVNsbkpBRW9Qb0lEbHZHVU1ZYUY5Q2xBallsWlZsQmFZXzBueFZwaUNfRUh3Y3NUTS1PbWlLUXpKT3E0ZzdkQU5reWl3VnpCYlc5dWpuV1BMeDY3OThBcm1ieVR2bVZ6?oc=5" target="_blank">LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
BioArctic CEO Osvalt Says Home-Administered Leqembi Auto-Injector Is Just the Start; Parkinson's Data Looms
BigGo Financepolitics

BioArctic CEO Osvalt Says Home-Administered Leqembi Auto-Injector Is Just the Start; Parkinson's Data Looms

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE9EbDRSRzZnOFZxVmNFU0EtYkkxUGlZMHdvNkd0ZkwzY2ZESENGX3NyeG1aUXZLaDhsT2VDeTh6ckYxX3I3M182X1lvMU9UaVRhdGJ3S3FHa3JUWlU?oc=5" target="_blank">BioArctic CEO Osvalt Says Home-Administered Leqembi Auto-Injector Is Just the Start; Parkinson's Data Looms</a>  <font color="#6f6f6f">BigGo Finance</font>

Read Full StoryMore like this
Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing
Fierce Pharmatech

Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbm1PRFRleEVqcmxQS3YxVzE2bjE1WE5JS1ZFMEs2WS1PUEprTnZwaVQ0SVZQX0t0OUFDOFVPeVh0WGM4MURxZ0VQdmRBVWFSQ01qeXYwYWxRbzlRcHdaRHhKd2JaMVBBLXZEUjMwTkxRQVNHMDEyM1ZxMkkyQWpTbWJZcVI4WmNxSDdaOFRJS2k2WmpJM2pOZ1lNcHR3M2ZGeWVVR3ByV0JSbmtuYnFZV3FzZnpMRHd5TmsxbmdxbXI?oc=5" target="_blank">Eisai secures FDA green light for Leqembi autoinjector, teeing up at-home maintenance dosing</a>  <font color="#6f6f6f">Fierce Pharma</font>

Read Full StoryMore like this
FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease
Pharmaceutical Executivegeneral

FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQVllXRTZxTzI0Y3U1dVUzTklYWEh3dkRYWGR3aHJhOE1UaTdsT1JiTzUyZmtVSzFXa1hNWFlhNkgtWXJpa0Z6U191NE9iNlhGam5MaWJhVmR6OTNkQ3lEc1RYTkoyRXVsdWUzSFZ6YzI1Y29sbW03UFA2Q216U3YwYTNFU0VyVVNGRzRQa0YtemxFbmFCekdMSlVLMVA?oc=5" target="_blank">FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves Leqembi Iqlik Subcutaneous Injection as Initiation Dose for Early Alzheimer's Disease
BioPharm Internationalgeneral

FDA Approves Leqembi Iqlik Subcutaneous Injection as Initiation Dose for Early Alzheimer's Disease

<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOSGYwSXlXOXZfbERkaU9EM29rQ3RmMDdWWlA3clJNSGtyZmt1dzZ5YTRjLS1zUWdhYmE5VlE3bVUtN2Q2N1dnLWp4V1FYekt2MHlpYmg4QnRLcEpqQ1dvMHlRLWJIX0RWLUxVMU1ZLTl0NGF5dW45elRFbHdscUVMYzJkc2dBUFpIOWhjUUNfRENhYzctVjc1WTVHNTlQTDdZR1RpcnlGaW9oU0JsdGoxY0JpM2tJd19jQVRqU0ViSk9YN1hlSnIzY2l6Y3A5aEQtTnlUdmxnS2U?oc=5" target="_blank">FDA Approves Leqembi Iqlik Subcutaneous Injection as Initiation Dose for Early Alzheimer's Disease</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease
Eisai Co., Ltd.tech

New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE45dmF3c0JDd2M5SUV4RS1saC1TVEpoVEtiejh6Q3hJOVRFUlQ4SkxISkdlT29mRmdLME90Ymc5Y2Mtb1ZtRVJGamFZcFVmbmpVUjU0WmpwNVd6SjA?oc=5" target="_blank">New Data Presented at AAIC Demonstrates Investigational LEQEMBI® (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer’s Disease</a>  <font color="#6f6f6f">Eisai Co., Ltd.</font>

Read Full StoryMore like this
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease
GlobeNewswiregeneral

LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMikgJBVV95cUxNZjN3UVRFMHl6eFljMF9FQU9nZ2xZd0xYOVZldFpUSlRUcEZrWFpNVzNLWmcyS1hSYmNBaDFDWlhkNDhPSG16aklQRzlZOG55Z1RDajQ2cHhQcE40Z2lhd3FFZDViSUl4NnBSM1pIRGRzTHNaS1pEamRoYXUtRkhLRVl1R3RDOERrNHlWbk1UczRlWjhOSXB2RnJMenFNd25jTG9mS09tQXZJbnJEV210alhCbVd5NG5BLVp5eGVTOTFyUUVQampzc3Z6UE03SVczRVctRDg3MVBtT2EySXJOeGtIeWhpZTh0YWNoQ1JEM2VJaVRtN0NQbjNEWDkwajVwcXRwNjBoYjh0Qk5CcF9COVVn?oc=5" target="_blank">LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer’s Disease</a>  <font color="#6f6f6f">GlobeNewswire</font>

Read Full StoryMore like this
Leqembi® Pen subcutaneous formulation approved in Japan
Yahoo Financegeneral

Leqembi® Pen subcutaneous formulation approved in Japan

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWF9Uc282OTkya2pBWnhWQ2E1RGI0VldkUTA5Z0xIZnJEWjU4X2ZnOXRsS1NTMmxwU0x1dFE3SHhVY1JFVDBOUi1mS2w0azFiS0xlLWZCdkV2ajZXaGtfd0VpYlIxS0pldzFKNm1LSjVaVk82Q011cXVjeEwwckNLdWNpd1hBZmx4SnJ3bFhROGtWd0NVaHUxQ1Y0Q3BYeWNrVTdXbUkxWTZYdw?oc=5" target="_blank">Leqembi® Pen subcutaneous formulation approved in Japan</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Phase III Trial Shows Leqembi Subcutaneous Autoinjector Demonstrates Comparable Efficacy, Safety to IV for Early Alzheimer Maintenance
Applied Clinical Trialstech

Phase III Trial Shows Leqembi Subcutaneous Autoinjector Demonstrates Comparable Efficacy, Safety to IV for Early Alzheimer Maintenance

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPSVRuZ2R1QjBINEVBN3V3X0U5Y3pXWlJncHRFeVJQUDV5eVQ0ZlJTSTRGZEw1VjNLcnhLT3UwMXJlUHZqWEppR0tWR3RhY1F5bjJhemt4VUZndUtCR1FBYXg4NExXQ1hpZ2N0UGhpYjNrSG01aU5MckNHLWt3aFBkb1ozR1FvQU4zRTdTdWZuZ295cldRX2pnMzhKY3Fsa0l4WUV5SGp6aVpDNnBnbEViQ1o4UXg5VWFnaGR0VUp0TWpMQzg1VUE3NEpPb1U3WmhJNU1Wd3ctOGpMa2MwZmtuWUFraXlGakM2dkpEbg?oc=5" target="_blank">Phase III Trial Shows Leqembi Subcutaneous Autoinjector Demonstrates Comparable Efficacy, Safety to IV for Early Alzheimer Maintenance</a>  <font color="#6f6f6f">Applied Clinical Trials</font>

Read Full StoryMore like this
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Biogengeneral

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQd1JkMUwtM0lxWF9nQTF3UEpYTTlwWFZfOXhkcE5WVjVTUmZfUWxoN2Jqa0RhdkhTM1hwX1M5dC01bEtTSV9hM2h2NEJYekxaczlJVkNmSTYzS2tkZW5HdE1nMkFHbXlwVUpjazhsMEJZX3E2LWZiVVBSXzhZTnJReVJDV253NTVvMVNFb3c0VnZ6T3VCbmpDaVRZVlJvY1BzVmRWMTBVSVo5VWdJUVF0aFVXRnJ2bXZFQnNtOTRSbw?oc=5" target="_blank">Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
FDA approves Eisai and Biogen's subcutaneous Leqembi, gaining new ground in competition against Lilly
Endpoints Newstech

FDA approves Eisai and Biogen's subcutaneous Leqembi, gaining new ground in competition against Lilly

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPbm9fWXVzVldjUFN5Y2Zid0drV2NUZ2hkSF9FcWNDN18zQ0VwY0RsbGxGTHVJclc4Vm5LMEJ1MGxXNE1OS19wWS12YnZsZXQza1pXYzBaQzZ5ZjI2QmpxamppNlVhY0h2dEE1am1DMUZRd0F1R1VXZTZZQlI1WHo3Uw?oc=5" target="_blank">FDA approves Eisai and Biogen's subcutaneous Leqembi, gaining new ground in competition against Lilly</a>  <font color="#6f6f6f">Endpoints News</font>

Read Full StoryMore like this
FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection
Pharmaceutical Executivegeneral

FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPc0ZqZFBlUzFmMXl3ZkN0ekIxT1JjNHNXd3JvUG93aEEwRHlCZzNETzhiT1NKT1NLZFpxMWprNkduc2ZoVWVwSF9RZkRnMkhrektKSVdsWHdwNzBPc21kNWJwQUxFclJTakE2eE1qSkU5QjdUd0d4eHZrbW9hOHVjOFlxODdWOVBSV0QxVVliclhBcUhibU1DSGp5MA?oc=5" target="_blank">FDA Extends Priority Review of Leqembi Iqlik Subcutaneous Injection</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves Biologics License Application for Leqembi Iqlik Subcutaneous Injection
Pharmaceutical Executivegeneral

FDA Approves Biologics License Application for Leqembi Iqlik Subcutaneous Injection

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQbHdCWG1TT2RMMkdiOXc4Z2dqMTR5eTlhVEpzUHRISzc3bG9LLUpuR1BGYkxCXzBUZzM2UFVpTkJnOTdaTkhqMC1kc1BLeFFjYnJieXFtNHVNUEJRemNidzlRVlhZbGY4VUxkeDlTeXpvSk1iYnlmSm1TeE9lRU1PaVpwbzFuTFk1QXI0QzB3dTBlQlJyMmhnT0hNTGdCMmRlcGxmTDlQY0RDTW0xTjVV?oc=5" target="_blank">FDA Approves Biologics License Application for Leqembi Iqlik Subcutaneous Injection</a>  <font color="#6f6f6f">Pharmaceutical Executive</font>

Read Full StoryMore like this
FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Biogentech

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQRDJ3S2FGX3daTm41ejhpZS1CRmtPemRUMGJBdE5mRFZFMDZjRzhKNHptWVRIRG9rc3JsbzkzbnFpZEVQYlJ2a09pNnBXYUVuZW5FcXE4TThQdmktR05adVRHeGVoZU02ZnU0R3FQRldVLTBIdGVQZUV3V3JTaTBnQ0R6MDlNY3IteDBqdXpkZ0JENzJjSTU0aXdHaWVXN1pNTkR4STgyR2piTk43NmVaNFkwMVNiWWNNWUpQWnBR?oc=5" target="_blank">FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Biogentech

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVGdHRmhLT2ZIWjRwMk95bUJVdVVnRXJMQk9FdHhRRThILWRUMWhjZEZWelRhXzZwcjV4Y2lWRTBTcHBZdC1FbFdwenpnRWNsd2ZTc3ZKLXdBSGpvM0Nsc2FXOERfTExRWk4wLU9JV1dQMDM3NGVodmxPNTIwRFNtdUlKYUZGT1AyQWU0N1JHY0RvUkh3MllQMTl5aGVDRnVZdUhoSGRLSElWSXE4bW45YXRIYUktbHJs?oc=5" target="_blank">FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease</a>  <font color="#6f6f6f">Biogen</font>

Read Full StoryMore like this
FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab
NeurologyLivegeneral

FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNaDY2MUpUTlVyYW5oMUdwX1ZuTkhxR3BQQzktcG1Vb205UU4yUWxWYm1KMm1LU2pQRFlBNWRIdVQ0dTZvV09jRnJReDR3LWo3MENyN0RySkpXWHExb2dmdVhia0xSOEFwMnVUYnNMUHAwTUZEUkk4MHlPcDV1bjJDVUh6S3dReXhvOGF5VkRfTUE1dkE5NXlFV0pKSm8xVUE?oc=5" target="_blank">FDA Accepts BLA for Subcutaneous Autoinjector Formulation of Lecanemab</a>  <font color="#6f6f6f">NeurologyLive</font>

Read Full StoryMore like this
"LEQEMBI® Subcutaneous Aut" — Live Google News Trends & Headlines